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Performing intensity-modulated radiotherapy (IMRT) on head and neck cancer patients (HNCPs) requires robust
training and experience. Thus, in 2011, the Head and Neck Cancer Working Group (HNCWG) of the Italian Association
of Radiation Oncology (AIRO) organized a study group with the aim to run a literature review to outline clinical practice
recommendations, to suggest technical solutions and to advise target volumes and doses selection for head and neck
cancer IMRT. The main purpose was therefore to standardize the technical approach of radiation oncologists in this
context. The following paper describes the results of this working group. Volumes, techniques/strategies and dosage
were summarized for each head-and-neck site and subsite according to international guidelines or after reaching a
consensus in case of weak literature evidence.Introduction
Performing intensity-modulated radiotherapy (IMRT)
in head and neck cancer patients (HNCPs) requires
training [1] and experience. For example, in the 02–02
Trans Tasman Radiation Oncology Group (TROG)
trial, comparing cisplatin (P) and radiotherapy (RT)
with or without tirapazamine, a major quality defect of
the irradiation approach in terms of dose and target
volume selection and delineation was found in 12% of
patients and was associated with a 24% lower loco-
regional control rate at 2 years [2]. Hence, in 2011, the
Head and Neck Cancer Working Group (HNCWG) of
the Italian Association of Radiation Oncology (AIRO)
organized a study group to outline clinical practice
recommendations regarding techniques, treatment vol-
umes and doses to be employed during head and neck
IMRT. The main purpose was to standardize technical
approaches of professionals participating into AIRO head
and neck cancer trials.* Correspondence: elviorussi@gmail.com
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The first participants (AM, DA, AM, LL, RM, GG, OC,
FM, FD and RC) were chosen on a voluntary basis
among the HNCWG members. The group was coordi-
nated by an expert head and neck radiation oncologist
(RC). Each member was in charge of a specific topic.
At the end of the first draft (February 2012) the whole
document was reviewed by all the HNCWG members
in order to discuss critical issues and to homogenize
the manuscript structure. The revised draft was again
reviewed by 5 radiation oncologists with particular
expertise in head and neck IMRT (RVT, PF, SP, ER
and GS).General aspects
Treatment strategy
RT is one of the mainstay treatment options for head
and neck cancers (HNCs), along with chemotherapy
(ChT) and surgery (S). In general, RT ± ChT is the pre-
ferred approach for head and neck squamous cell carcin-
omas (HN-SCC) whenever organ preservation is desired
or the tumor is unresectable at presentation (cT4b) or
the patient is considered not amenable to surgery. For
early T-stage lesions (cT1 and selected cT2) withoutl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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monomodal (RT vs S), while for locally advanced disease
(cT3-cT4 or any T,cN+), treatment is usually multimodal
(S followed by RT ±ChT vs RT and concomitant ChT ± S).
Concomitant ChT (usually platinum-based) has been
shown to increase overall survival (OS) in stage III
and IV disease over RT alone [3]. Recently published
long-term results of the RTOG 91–11 trial in larynx can-
cer failed to show such an advantage over sequential ChT-
RT because of an increased number of non-cancer-related
deaths in the concomitant arm, suggesting a higher long-
term toxicity rate for ChT-RT [4]. Induction and adjuvant
ChT are less effective than concomitant ChT [3,5]. How-
ever, within an organ preservation strategy, induction ChT
may become an option to select responders who might
potentially benefit from an organ preservation approach,
driving eventual further treatments (S vs RT) on the basis
of response to neoadjuvant ChT [6,7]. Recent published
trials found no benefit from the addition of Taxotere(T)-
Platinum (P)-5Fluorouracil(F) induction ChT to concomi-
tant ChT/RT or cetuximab-RT compared to concomitant
ChT/RT or RT alone [8-10]. Another alternative to con-
comitant ChT is cetuximab, an epidermal growth factor re-
ceptor inhibitor, which, combined to RT, has been shown
to provide a better OS than RT alone in HN-SCC [11].
However, Erbitux has never been tested against the
standard treatment (concomitant platinum-based ChT-
RT) and consequently its role is somewhat unclear.
Moreover, when Erbitux was added to concomitant
ChT-RT, no additional benefit was found [12]. After
concomitant ChT-RT, S is usually reserved for eventual
locoregional disease persistence. Regarding neck man-
agement, most Institutions nowadays use FDG-PET/CT
at 10–12 weeks to select patients at risk of for residual
nodal disease [13]. The decision to add adjuvant treat-
ments after upfront surgery is made once the pathology
report is available. RT is usually added for high risk fea-
tures including positive resection margins (PRMs),
advanced T stage (selected pT3 and all pT4), perineu-
ral invasion, lymph-vascular invasion, any nodal stage
higher than pN1, and extra-capsular lymph-nodal ex-
tension (ECE); ChT is added for PRM and ECE. There-
fore, treatment is usually multidisciplinary and any
decision should be discussed within the tumor board
involving all specialties. Aspects such as nutrition, oral
care and restoration/preservation of swallowing and
phonatory function (speech therapy) are also important
and should be considered whenever feasible.
IMRT (Intensity-Modulated Radiation Therapy)
Though few Institutions pioneered IMRT for HN-SCC
during mid-90s, this technique has become widespread
during the last decade. The aim of IMRT is to achieve
more conformal dose distribution over standard 3Dconformal RT (3DCRT) and this in turn allows for better
sparing of normal structures (i.e. parotid glands). This
potentially translates into fewer late side effects (xeros-
tomia) and improved quality of life [14]. With IMRT,
the physician identifies the target volumes(s) and the
organs at risk (OARs) appropriate for a given clinical
condition. The dose to the target is usually proportional
to the estimated tumour burden (Table 1 and Figure 1).
It should be noted that the maximum prescribed dose
has empirically evolved as the highest tolerated dose tak-
ing into account the surrounding normal structures. A
‘definitive’ treatment typically includes 2–3 dose levels
within the same patient. Using IMRT a different dose to
different targets can be delivered with sequential plans
(as for 3DCRT) or with a simultaneous integrated boost
(SIB). It has been shown that the latter approach pro-
vides better dose conformity compared to several con-
secutive plans [15]. When a single plan is prescribed,
CTV1 receives both a higher total dose and a higher
dose/fraction (d./f.) compared to the other CTVs. This
results in an even higher biologically equivalent dose
(BED) compared to other CTVs. However, since all dose
levels are delivered throughout the same number of frac-
tions, targets must receive different fractionations.
Two solutions have been proposed [16] (see Table 1).
The first approach is to maintain conventionally frac-
tionated doses to the highest dose CTV (1.8-2 Gy per
fraction) (Table 1) whereas the elective targets receive a
lower d./f. (1.6-1.8 Gy). The choice of the latter is made
taking into consideration the normalized total dose in
2 Gy fractions (NTD). The second strategy is to deliver
a slightly hypofractionated dose to the GTV and stand-
ard fraction doses to the CTVs [17]. Each strategy has
pros and cons and no universally accepted schedule has
been developed. The former solution may lead to the
use of a very low d./f. according to current standards; a
daily d./f. below 1.6 Gy should be avoided. Notably, in
one study, 58.1 Gy in 35 fractions were able to control
the microscopic low-risk disease [18]. The latter ap-
proach has the disadvantage of using a higher d./f. (up
to 2.5 Gy) than the standard fractionation for the GTV
potentially exposing normal tissues embedded within the
high dose CTV to the risk of increased late toxicity.
Moreover, this results in a higher than standard weekly
total dose to normal tissues (i.e. mucosa) within the high
dose region. According to some authors [19], 66 Gy/
30 f. (2.2 Gy) should not be used in the context of con-
comitant CT. On the other hand, a d./f. up to 2.12 Gy is
used in the context of concomitant CT (P, 100 mg/m2 x
3 cycles) for nasopharyngeal cancer [20]. Recently some
authors have reported initial experience in advanced
HNC with a d./f. up to 2.25 Gy in 30 fractions concomi-
tantly to CT. This schedule seems feasible with an ac-
ceptable but not negligible acute toxicity rate, while a
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Figure 1 Volumes at risk in HNC (a) Definitive and b) postoperative RT). The Question mark "?" refers to the uncertainty of the tumour-cell density.
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[21,22]. In conclusion, hereinafter we will refer to IMRT
as a SIB approach. The choice of the fractionation
schedule (d./f.) is left to each Institution taking into
account the aforementioned considerations. Whenever
available, we will refer, for each primary site, to the
fractionation schedules that have been tested clinically.
We encourage each Institution to follow patients and
investigate its own pattern of failure.
Practical implications of induction/concomitant CT
HNCs are typically treated once a day, i.e. 5 fractions
per week (f/w) (standard fractionation). Although a few
studies, and one meta-analysis, have shown better loco-
regional control rates, and even improved survival, when
multiple fractions per day are delivered [23-25], it is
doubtful whether the treatment acceleration (more than
5 f/w) is beneficial also in the context of concomitant
CT. Two randomized studies [26,27] failed to show an
advantage of concomitant chemo/accelerated-RT over
standard CT/RT. Moreover, there are practical limita-
tions in the number of treatment sessions that can be
delivered per day with IMRT due to its workload inten-
siveness (each treatment session typically takes more
than 15 minutes). RTOG [26] adopted a mildly acceler-
ated radiation schedule (6 f/w) with concomitant CT as
a standard, delivering the 6th fraction as a second daily
dose on Friday (at least with a 6 hour gap) or on
Saturday. In the context of concomitant CT there are no
clinical data showing the benefit of multiple fractions
per day (or more than 5 f/w) or a single fraction per day
higher than 2 Gy.
Regarding induction CT, one potential advantage/pit-
fall is the potential downsizing of the primary tumour
and lymph nodes. This can be successfully exploited in
selected situations where the delivery of the highest doselevel is limited by the tolerance of the surrounding nor-
mal structures (i.e. optic pathways for T4 NPC) [28]. On
the other hand, it has been recommended that the initial
rather than the post-chemo volume should encompass
the high-dose region during contouring and planning
[29]. With this in mind, the planning session should be
carried out both before and after induction CT, if pos-
sible using the same immobilization device.Practical implications of upfront surgery
Extensive surgery can disrupt normal anatomy and vio-
late tissues that generally are not considered at risk of
microscopic disease. In general, the whole operative bed
is considered at some/low risk after surgery, with the ini-
tial site of disease at highest risk. This implies that, when
a flap reconstruction is performed, the whole flap should
be included at least in the lowest dose volume. Regard-
ing the whole operative bed, doses in the order of 50–
54 Gy (2 Gy per fr) have been used [30,31]. It should be
noted that the ‘classical’ recommendation is to include
any surgically violated sites regardless of final pathology
(i.e. the dissected neck that is found to be negative, pN0,
should still be included in the lowest dose level)
(Table 1). Regarding the initial site of disease, its identifi-
cation is best based on pre-surgery imaging studies and
operative notes. When incomplete resection is sus-
pected, a repeated PET/CT at > 1 month after surgery
has been shown to detect macroscopic residual disease
in a significant proportion of patients [32]. Postoperative
treatment should be started as soon as healing takes
place (usually 2 weeks) and not later than 6–8 weeks
after surgery [31]. Patients who fail after surgery may
have a peculiar lymphnode-invasion pattern due to the
distortion of normal lymphatic flow. Therefore, in this
setting, lymph node involvement may be less predictable
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ate from the recommendations here provided.
Pre-treatment evaluation
The following procedures are recommended before
starting RT:
1. Biopsy of the primary lesion. Fine needle aspiration
(or more aggressive procedures) of suspicious lymph
nodes may also be an option when the primary
lesion is not evident (cTx) or when the presence of
positive lymph nodes may have prognostic and/or
therapeutic implications (i.e. definition of treatment
volumes or the addition of CT).
2. Panendoscopy under general anaesthesia with ‘blind’
tongue-base, tonsillar fossa, pyriform sinuses,
Rosenmuller fossa biopsies or unilateral/bilateral
tonsillectomy in unknown primary tumours.
3. Anamnesis (including tobacco and alcohol use,
sexual habits, and current medications) and medical
examination (including weight and performance
status evaluation).
4. Indirect laryngoscopy and flexible endoscopic
examination.
5. Complete dental evaluation (except for those
receiving narrow fields for larynx cancer). Any
required dental extractions must be perfomed and
fluoride prophylaxis instituted prior to RT.
6. Speech pathology evaluation, including instrumental
and/or clinical swallowing assessment and
administration of pretreatment swallowing and
trismus exercises, completion of pretreatment QoL
questionnaires.
7. Nutritional evaluation.
8. Completion of the following laboratory studies: CBC
(complete blood count), metabolic panel including:
sodium, potassium, glucose, calcium, magnesium,
BUN (blood urea nitrogen), serum creatinine, total
protein, albumin, alkaline phosphatase, total
bilirubin, AST, ALT, creatinine clearance, and
thyroid function (TSH).
9. Completion of the following radiological studies:
9.1 Head-and-neck CT with <3 mm contiguous
slices (with contrast enhancement, unless
contraindicated);
9.2 Whole body 18FDG-PET/CT scan for locally
advanced disease and for unknown primary sites
(integration of both high resolution contrast-
enhanced CT and dedicated PET acquisition
through the head and neck region are strongly
suggested; as an alternative, CT of the chest ± ab-
domen, in particular for salivary gland tumours);
9.3 Head-and-neck MRI with gadolinium including
T1- and T2-weighted sequences in at least 2different planes (strongly suggested for tumours
involving the tongue base, salivary glands and
nasopharyngeal cancer).
10. Audiogram is recommended if the inner ear is to
be irradiated at mean dose ≥ 40 Gy.
11. Post-operative MRI/CT, pre and post-operative
PET (optional);
12. Testing the tumour specimen for Human Papilloma
Virus (HPV) is also strongly recommended via
in-situ hybridization or, indirectly, via p16 IHC
(Immunohistochemistry) for oropharyngeal
cancer, WHO-Type 1 nasopharyngeal cancer, and
unknown primary tumours [33]. Testing the
tumour specimen for Epstein Barr Virus (EBV) is
strongly recommended for both nasopharyngeal
and unknown primary tumours.
Simulation
1. The patient is usually set up on the treatment table
in supine position. The immobilization device is
generally a thermoplastic mask immobilizing both
head and shoulders [34]. A mouth piece is also
indicated for all non-edentulous patients. A tongue
depressor is generally not recommended except for
tumours of the nasal cavity and paranasal sinuses
(to move the tongue and the mouth floor away
from the irradiated volume) or for tumours of the
bottom of the oral cavity (to displace the upper
part of the oral cavity). Dental prostheses have
to be removed. The position of the head is usually
neutral and comfortable except in selected situations
detailed in each section. The patient is instructed to
breath normally/quietly and not to swallow during
scanning. Scars are usually wired. A 3–5 mm
bolus over the larynx is also optional depending
on the beam energy and the patient’s thickness
when the larynx is part of the target (especially
for lesions involving the anterior commissure
and beyond). A 3–5 mm bolus is also to be
considered over areas of skin infiltration and/or
after surgery in case of nodal extra-capsular extension
(ECE).
2. Treatment planning CT scan should be performed
having the patient in the treatment position. I.V.
contrast liquid administration at the time of
simulation is also recommended. MRI-scan
planning is optional.
3. CT-scan thickness should be 0.3 cm or less through
the region that contains the primary target volumes.
The regions above and below the target volume may
be scanned with slice thickness up to 0.5 cm. MRI
and PET/CT scans may be included to assist in
defining target volumes as appropriate.
Merlotti et al. Radiation Oncology  (2014) 9:264 Page 6 of 324. The GTV, CTV and PTV and normal tissues are
outlined on all the appropriate CT slices.
5. Patients should be trained to avoid swallowing in
order to reduce organ motion during treatment.
Volume and ICRU reference point definitions
The definition of volumes is in accordance with ICRU
Reports n° 50 [35] and n° 83 [36]:
1. The Gross Tumour Volume (GTV) is defined as
all known gross disease determined by CT, clinical
information, endoscopic findings and MRI in case
of tumours treated after biopsy alone. Functional
information can be used to define sub-GTVs that are
to receive some additional absorbed dose [37].
Typically, different GTVs are defined for the
primary tumour (GTV-T) and the regional node(s)
(GTV-N). Yet in those clinical situations in which
the metastatic node cannot be distinguished from
the primary tumour, a single GTV encompassing
both the primary tumour and the node(s) may be
contoured (GTV-TN) [38].
Furthermore, in consideration of adaptive RT,
any changes occurring within the GTV during
treatment can be quantified with anatomic- and/or
functional-imaging techniques, allowing for the
definition of a modified GTV in order to adjust the
absorbed-dose distribution [39,40].
Thus, because GTV contouring can vary according
to the diagnostic modality used (e.g. clinical
examination, anatomic and/or functional imaging)
and the time/dose of acquisition with respect to the
start of treatment (e.g. in the case of adaptive RT),
a clear annotation is required. For example, ICRU 83
recommends specifying the imaging technique and
pre-delivered dose: e.g. GTV-T (MRI-T2, 30 Gy),
GTV-T (clin, 0 Gy).2. The Clinical Target Volume (CTV) is contoured
by the treating physician and is defined as a volume
of tissue that contains a demonstrable GTV and/or
subclinical malignant disease with a certain probability
of occurrence considered relevant for therapy [38].
The notion of subclinical malignant disease includes
the microscopic tumour spread at the boundary of the
primary-tumour GTV, the possible regional infiltration
into lymph nodes, and the potential metastatic in-
volvement of other tissues. The selection of the tissues
that bear risk for microscopic infiltration outside the
GTV is a probabilistic assessment integrating the
biological and clinical behaviour of the various tumour
entities. Consideration may also be given to the
presence of any specially radiosensitive normaltissue (Organs at Risk) as well as to other factors
such as patient’s general conditions [35].
2.1. Clinical experience indicates that in the region
around GTV (Figure 1 a,b) there is generally
subclinical involvement, i.e. individual malignant
cells, small cell clusters, or microextensions,
which cannot be detected through clinical
staging procedures. The GTV together with
this surrounding volume of local subclinical
involvement can be defined as a clinical
target volume (CTV-T for primary tumour,
and CTV-N for metastatic lymphadenopaties,
etc.). If the same dose is prescribed for two
such CTVs and if they are close to each other,
they can be labelled CTV-TN. This volume
has to be considered for therapy and, if in-
cluded, should be irradiated adequately to
achieve cure. The margin between each GTV
and its CTV should be typically 10–20 mm,
with a minimum of 5 mm except in those
areas where the GTV is immediately adjacent
to structures known to be uninvolved (i.e.
anatomic barriers). To account for the risk of
extracapsular spread, a margin should also be
added to the involved nodes [41].
2.2. Additional volumes (CTVs) with presumed
subclinical spread (Figure 1a,b) (e.g. regional
lymph nodes, N0) at a distance from a GTV
also need to be considered for therapy [42]. In
this situation the prescription is based on the
assumption that in some anatomically definable
tissues/organs, there may be cancer cells at a
given probability level, even though they cannot
be detected as they are subclinical. The level of
probability is based on clinical experience from
adequately documented treatments and follow-up.
For the purpose of treatment prescription, it can
usually be described in terms of frequency of risk
for later detectable manifestations (failure rate),
when untreated adequately in the subclinical
setting [43]. There is no general consensus on
which probability is considered relevant for
therapy [18,38,44], but typically a probability of
occult disease higher than 5-10% is assumed to
require treatment. However, the volume could be
defined as at “high-risk” (CTVHR or CTV2) or
“low-risk” (CTVLR or CTV3) (Figure 1a/b) in
consideration of the probability and entity of
microscopic infiltration and could be targeted at
different dose levels [18,41,44].
Moreover, in HNC the probability of
pathologic lymph-node involvement has been
well described, and the distribution follows a
predictable pattern allowing clinicians to tailor
Figure
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extent [18,45-47].
In postoperative cases, the CTV includes the
operative bed and adequate margins according to
an assessment of the risk of subclinical disease.
The contouring of GTV and CTV are based on
purely anatomic-topographic and biological con-
siderations (morphology, such as ulcerative or
exophytic, infiltrative or pushing front) with no
regard to technical treatment factors [35,43].
Consequently, rather than simply expanding the
GTV uniformly, it is recommended that the CTV
should be contoured on a slice-by-slice basis [48].
Hereinafter, peri-GTV, CTVHR and CTVLR will
be respectively defined CTV1 (e.g. CTV-T 1;
CTV-N 1; CTV-TN 1), CTV2 and CTV3.3. The Planning Target Volume (PTV) will provide a
margin around each CTV to compensate for the
uncertainties of treatment set-up and tissue
deformation. An isotropic expansion of 5 mm is
typically added around the CTV to define each
respective PTV. For patients undergoing daily IGRT,2 Nasopharynx. Countered volumes (before and after ChT).the margins are sometimes cut down to 3 mm, though
this is controversial [49]. Margins can be further
expanded in special situations (i.e. concerns on set-up
error). Nevertheless, institution specific margins are
strongly recommended.
4. In patients who receive neoadjuvant CT, the post-
CT GTV will differ from what is seen on diagnostic
images and the former should be outlined. The
CTV, however, should be tailored to encompass the
preCT GTV [29] (see Figure 2).
5. To facilitate planning a suffix indicating the
prescribed dose to each CTV should be used, e.g.
CTV70, CTV60, CTV50, etc.
6. Unless otherwise specified, here we will refer to the
3 definitive and 2 postoperative dose levels as
reported in Table 1.Primary-tumour contouring (GTV-T): high dose volume
(CTV-T 1)
The GTV is usually defined based on physical examin-
ation and imaging findings. While the addition of MRI
to CT contributes to improve tumour detection and
observer consistency, the role of functional imaging to
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gard the information from FDG PET-CT [50].
Once identified, the GTV is usually expanded to its
corresponding CTV (CTV1) by 0–10 mm depending on
the presence of anatomic barriers, image quality and the
presence of artefacts (dentures). With 3DCRT the whole
portion of the sub-site, or a major part of it, is included
in the CTV1 (e.g. the whole larynx and the whole
rinopharynx in the case respectively of laryngeal and
nasopharyngeal primaries). Conversely, with IMRT
and according to ICRU directions, there is the ten-
dency to limit the high dose region to the part of the
sub-site, involved by disease.
Positive neck nodes (GTV-N): high dose volume (CTV-N 1)
Lymph node stations or levels in the neck follow the
surgical nomenclature. Cervical nodes are usually con-
sidered positive on contrast-enhanced CT scans if they
show one or more of the following features: maximum
axial diameter > 1 cm (5 mm if retropharyngeal); oval/
round as opposed to reniform shape; suspected focal
necrotic hypodensity; irregular enhancement pattern;
presence of extra-capsular penetration as judged by
spiculated margins [51] and clusters of 3 or more bor-
derline nodes [52]. A station is considered positive if it
contains positive lymph nodes. For positive nodes, a
‘full’ radiation dose is usually recommended. However,
in this case, only the positive lymph node(s) and not
the whole station is (are) contoured as GTV. More-
over, expansion from GTV to CTV1 does not imply
that the whole level would be part of CTV1. Some
authors would add 5 [41]-10 [53]mm around the GTV
of lymph nodes to account for potential subclinical
(extracapsular) spread [41].
Intermediate dose volume: high risk volume (CTV 2)
Within a definitive treatment, the definition of the
intermediate dose region is highly subjective, variable
across Institutions [18] and considered optional. Ideally
it would correspond to the regions at high risk of con-
taining microscopic disease (>10-20% [54,55]), prefer-
ential regions of diffusion around the primary tumour
[56] or lymph nodes that are borderline or suspicious.
(i.e. between 7–9 mm in greatest axial dimension in
neck levels III through IV; with a rounded appearance
defined as a width to length ratio greater than 0.5; lack
of fatty hilum or a cluster of three or more borderline
nodes) [51,57]. The factors affecting this risk should be
taken into account for each case: tumour stage, size,
thickness (3 mm or more is associated with a high
metastatic risk for oral cavity tumours), differentiation,
keratinization status, lymphatic vessel invasion in the
tumour specimen, and whether other neck levels are in-
volved [16].Again, as for positive nodes, it is unclear whether the
whole level at risk should be included within a given
higher dose or only the suspicious node. We usually
favour the latter, since in one study all neck failures orig-
inated from pre-treatment suspicious nodes [18].
Elective neck contouring: low risk volume (CTV 3)
There are several definitions available for neck nodal
levels and here we will refer to the one used by coopera-
tive groups (RTOG/EORTC). Accordingly, there are sev-
eral papers and atlases that have reported guidelines for
nodal level contouring both without and after surgery
[47,58,59]. Compared to volumes treated with 3DCRT,
current definitions of neck levels provide only partially
overlapping volumes and the mismatch is particularly
evident for some levels (i.e. levels IB and V) [59]. How-
ever, once identified, it is possible to irradiate precisely
and selectively different node levels wit IMRT. Hereafter
we will refer to the neck nodal levels ipsi- and contra-
lateral to the primary site for each subsite.
Finally, it would be appropriate to include the whole
muscle (i.e. sternocleidomastoid muscle) in CTV3/LR or
when grossly infiltrated at some level.
Organ at risk (OAR)
Definition
Several OARs and tissues are routinely contoured on each
patient planning CTas follows: mandible/TM joints, brain,
brainstem, cord, parotid glands, upper gastrointestinal
mucosa, larynx, oesophagus, brachial plexuses, inner ears,
optic chiasm, optic nerves, ocular bulbs, lenses, major lac-
rimal glands, pituitary gland, submental connective tissue.
For planning purposes, the cord and brainstem are usually
expanded (by 5 mm) as well as the optic pathway struc-
tures (optic chiasm, optic nerves and both retinas) to form
a PRV (planning reference volume). PRV expansion, as
PTV expansion, depends on set-up accuracy and set-up
errors as well as on the IGRT technique.
Optional (that are usually not constrained) OARs in-
clude: submandibular glands, thyroid gland, mastica-
tory spaces, upper, middle, and inferior constrictor
muscles, crico-pharyngeal muscle, carotid arteries,
lung apexes.
OARs dose (volume) objectives
Dose volume objectives are summarized in the Table 2.
Contouring indications and structured atlases [60,61]





Table 2 Organs at risk
OAR [81] Priority Endpoint Goal Minor variation Comment
Cord PRIM 0.1 cc Dmax≤ 44-45 Gy Dmax 46 Gy
Cord (PRV) PRIM 0.1 cc Dmax 44–48 Gy Dmax 48–50 Gy
Brain PRIM 1 cc Dmax 60 Gy Dmax 63 Gy
Temporal lobes PRIM 1 cc Dmax 60 Gy Dmax 65 Gy
Brainstem (PRV) PRIM 0.1 cc Dmax 54 Gy Dmax 60 Gy
Chiasm (PRV) PRIM 0.1 cc Dmax 54 Gy Dmax 60 Gy
Optic nerve (PRV) PRIM 0.1 cc Dmax 54 Gy Dmax 60 Gy
Larynx PRIM 1 cc Dmax 73.5 Gy Dmax 77 Gy
Mandible PRIM 1 cc Dmax 70–73.5 Gy Dmax 75–77 Gy
Inner ear SEC D mean <50 Gy <52.5 Gy
Larynx (without cartilaginous framework) SEC V50 <25% <30% Oedema
Larynx (supraglottis) SEC Dmax <66 Gy Dysphonia
Larynx (whole organ) SEC Dmax <50 Gy Aspiration
Mandible SEC V55 <20%
Esophagus SEC 1 cc Dmax 45 Gy Dmax 55 Gy
Parotid gland SEC V30 <50% <60% at least one
SEC Dmean ≤26 Gy at least one
SEC V40 <33% (contralat)
Upper GI mucosa (outside PTV) SEC 1 cc <30 Gy <36 Gy
Upper GI mucosa (whole volume) SEC V66.5 Dmax 64 Gy (<3 %?) Dmax 70 Gy (<5%)
Brachial plexus PRIM 0.1 cc Dmax 60 Gy Dmax 66 Gy SEC in selected
Thyroid Gland SEC V45 <50%
Submandibular gl SEC Dmean <35 Gy
Constrictor pharyngeal mm SEC Dmean <50 Gy
Lacrimal gland PRIM Dmean 26 Gy SEC in selected cases
Lens PRIM Dmax <4 Gy <6 Gy SEC in selected cases
Retina PRIM 0.1 cc Dmax 54 Gy Dmax 60 Gy
Pituitary gland SEC Dmax <50 Gy
TM joints PRIM 0.1 cc <70Gy
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be standardized according to Institution guidelines.
The tolerance parameters reported here have only
an indicative value since they may vary significantly
among individual patients based on genetic factors,
co-morbidities, concurrent or previous treatments,
clinical status, habits and supportive treatments.
Moreover, it should be noted that dose fractionation
may influence the risk of both acute (weekly total
dose) and late (d./f.) reactions. The doses reported
below should to be considered equivalent to 2 Gy d./f.;
their use at a lower d./f. would be conservative, or
allow for extra safety.
PTV dose (volume) objectives
The process of developing a treatment plan consists of 3
components: (1) the definition and description of the“planning aims” and the desired absorbed-dose levels;
(2) a complex beam delivery “optimization” process to
achieve and, if needed, modify the initial “planning
aims”; (3) a complete set of finally accepted values,
which becomes the “prescription”. When optimized,
the absorbed-dose distribution is accepted by the
physician.
In the Literature different parameters regarding PTV
prescription and dose homogeneity are reported [62-64].
Hereinafter, the prescription dose is defined as the iso-
dose encompassing at least 95% of the PTV.
Target dose restrictions include the followings: no
more than 20% of any PTV could receive >110% of its
prescribed dose, no more than 1% of any PTV would re-
ceive <93% of the prescribed dose, and no more than 1%
or 1 cc of the tissue outside the PTV would receive
>110% of the dose prescribed to the primary target [17].
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 Split Field vs. Whole Field IMRT. Most Institutions
would plan IMRT for HN cancers considering the
whole volume (‘whole field IMRT’, WF-IMRT).
However, some Authors, especially in absence of
positive lymph nodes and for tumours above the
arytenoids (i.e. tonsil) propose the use of IMRT for
the upper part of the volume keeping a low,
anterior-posterior parallel-opposed beam approach
to cover the lower neck and the supraclavicular
nodes (‘split field IMRT’, SF-IMRT). The issue has
been highly debated in the literature [62,65].
Although there are pro and cons for each strategy,
our preference is to use WF-IMRT especially when
nodes are present in the mid/low neck to avoid
underdosing of the volume junction.
 Static IMRT vs. VMAT. IMRT takes several minutes
to be delivered and this may be uncomfortable for
the patient and workload intensive for the
Institution (a typical time slot for treatment reaches
30 minutes including IGRT). Tomotherapy allows
for the delivery of volumetric IMRT in a shorter
period of time and sharper dose distributions with
doubtful clinical impact [66]. Linac-based volumetric
IMRT, VMAT or Rapid Arc, offers the advantage of
less monitor units and shorter delivery times over
static IMRT [67], but no clear advantage (and
possibly disadvantage) in terms of target coverage
and OAR sparing. Although this is a rapidly evolving
field, the impression is that VMAT/RA may not offer
the same dose distribution of IMRT/Tomotherapy for
complicated cases [67]. Within this uncertainty, it
seems reasonable to implement VMAT/RA, at least
initially, in simple cases and with a dosimetric
comparison to standard IMRT.
 Tissue deformation during treatment. Most patients
undergoing RT ± CT for HNC may lose a significant
proportion of their weight (on averages 6% to 12%
of pre-treatment body weight [68]) during a 7-week
course. Sometimes, large nodal masses show a
dramatic shrinkage [69]; especially when adjacent to
surrounding normal structures (cord, parotids), the
dose distribution during treatment may deviate
significantly during treatment compared to initial
planning [70]. Finally, it has been shown that
almost all OARs undergo significant changes during
treatment, with about 30% of shrinkage for major
salivary glands, 10% for muscles (with the exception
of constrictors) and 15% increase for larynx and
constrictors [71]. The cord, the brain and other
nervous tissue structures seem unaffected. An
adequate supportive/nutritional treatment (including
enteral feeding) has proven to limit weight loss duringtreatment, increase patient compliance and ultimately
patient’s quality of life [72]. Which is the role of daily
IGRT and adaptive re-planning in this setting is still
undefined. Daily IGRT may reduce both systematic
and random errors and thus may be preferable over
weekly KV orthogonal films that address only the
former [73], though no firm clinical data support this
recommendation. One issue with the HN district is
the relative motion of structures, i.e. the mandible and
shoulders relatively to the neck and the deformability
of structures (i.e. neck curvature). These limit the
success of corrections using translations. Re-planning
should be currently limited to cases where the
changes in anatomy jeopardize the clinical outcome,
i.e. increase in dose to the cord due to shrinking neck
masses [70]. Fortunately, only a minority of cases
(<5%) show such modifications during treatment,
and overall most patients still fail within the high
dose region suggesting that geographic misses both at
planning and during treatment are not a prevalent
cause of failure. At present, rescanning of the patient
during treatment (with subsequent recalculation of
the dose distribution on the new planning CT ±
re-optimization) is considered at some Institutions
mainly in patients with significant (>10%) weight loss
or (nodal) tumour changes.
 Dental artefacts and tissue heterogeneity calculation.
Metal artefacts, in form of fixed intracavitary dental
alloys, may induce dose alterations with dose
enhancement that can lead to adverse tissue
complications in OARs in contact to or near PTVs,
and dose attenuation that may potentially spare cells
within the target volume.
 Two methods have been proposed to limit tissue
heterogeneity. A method that uses a model with
four different material classes: air, soft tissue, bone,
and metal. Pixels belonging to the same class are
assigned to the same representative Hounsfield unit
(HU). The HU of the pixels in the streaks resulting
from the presence of metal are replaced as much as
possible by the Hounsfield units of the soft tissue
class or bone class [74], thus reducing artefact
influence on dose calculation. Another method
uses MV-CT imaging obtained with the treatment
machine, with the patient in the treatment position,
that can be registered with the simulation kV-CT
scan for the purposes of structure delineation,
dose calculation, and treatment planning [75].
 Alternatively, a simple/basic empirical method is to
override tissue density in the metal region after
contouring. In this setting it is always prudent to
rerun the dose calculation with the original tissue
heterogeneity to better appreciate significant
deviations.
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target volume approaches the surface of the skin,
part of the PTV can extend into the build-up region
of incident photon beams or even into the
surrounding air (so-called in-air PTV). Most
dose-computation algorithms cannot accurately
compute absorbed dose in build-up regions. This
will lead to a convergence error, i.e., the optimizer
does not reach a global minimum for the objective
function [76].
 Two solution are usually proposed: i. The PTVs
are cropped so that they are restricted to 3 mm
below the contoured body surface to prevent
optimization issues in the build-up region except
for areas where the skin is considered a part of the
CTV. In the latter situation, a bolus is suggested,
as stated in the “simulation” chapter. In addition,
the PTV receiving lower dose is cropped from
the overlapping higher dose PTV to facilitate
optimization. After optimization, a skin flash
region (virtual bolus) is used to obtain a
sufficient fluence in surrounding air to cover the
original PTV. ii. Planning-target-volumes are
subdivided and a relaxation of the planning aims
is used (ICRU 83).
 PTV overlapping OARs. The second solution
proposed in previous situation is the preferred one
when there is a PTV/PRV overlapping knowing that
it is a trade-off between the coverage of the PTV
with the aimed dose and the saving of OARs within
the constraints.Oral cavity
Cancers of the oral cavity are usually managed by up-
front surgery and postoperative (chemo)RT. RT can be
used as primary therapy for small (T1, T2) tumours of
the oral cavity. Best results are with a combination of ex-
ternal beam radiation and brachytherapy.
IMRT is often used for oral cavity SCC to limit the
dose to OARs and primarily to the parotid glands.
However, compared to 3DCRT, it is associated with
longer delivery or treatment session time. This may not
be an ideal option for patients, who, especially after
extensive surgeries, due to accumulation of secretions
in the mouth, may not tolerate the supine position.
Sometimes suctioning secretions before treatment de-
livery helps to maintain the treatment position during
IMRT. Furthermore some initial reports with IMRT
register marginal failure especially in patients with
perineural invasion raising the question whether con-
ventional opposed lateral fields might be a better
option, also highlighting the importance of target de-
lineation [82] [83].Dose/fractionation remarks
Table 3 shows the commonly used fractionation regi-
mens in the curative setting.
Table 4 shows the commonly used fractionation regi-
mens in the post-operatve setting:
Primary-tumour contour
Definitive treatment
1. Table 5 describes anatomical landmarks in
contouring various oral subsites
2. At least a 1 cm margin around the GTV should
always be added. In cases where the extent of the
tumour is difficult to visualise it’s preferable to
use a 15 mm margins. CTV to PTV expansion
also need to consider the local motility of the target
(i.e. oral tongue) with respect also to the use of
immobilization devices (i.e. tongue depressor) and
their reproducibility. Anisotropic expansions (up to
10 mm) are often used to accommodate regions at
higher motility (i.e. the oral tongue).
Postoperative treatments
A positive margin on the oral tongue can be an indica-
tion for re-resection. Even when converted to negative,
an initial positive margin carries a worse prognosis than
an initially negative one [84] and thus should be consid-
ered at high risk of failure. In oral tongue cancers, peri-
neural invasion (PNI) is an adverse feature that qualifies
for adjuvant treatment at the primary site; moreover, in
case of PNI, the value of a negative margin is somewhat
questionable due to the possibility of a skip metastasis
along the nerve route. In case of direct nerve invasion, e.
g. if the inferior alveolar nerve is positive, the infratem-
poral fossa should be included in the radiation field
because cancer can spread retrograde through the nerve
into infratemporal fossa and to the skull base. The infra-
temporal fossa should also be included in the radiation
field for tumour adjacent to this nerve with extensive
perineural invasion and for tumour invading the ptery-
goid muscle, which is most commonly seen in patients
with retromolar trigone cancers [82].
The CTV3 includes the whole operative bed and recon-
struction site (i.e. free flap, mandibular reconstruction).
Lymph-node station contour
The neck (at least on the side of the disease) is often
dissected during the removal of the primary tumour. As
such, it is usually included in the lowest dose level re-
gardless of pathology findings (just because part of the
operative bed and thus potentially contaminated). A fur-
ther dose is best judged based on the final pathology
findings (high risk features, see above). Sometimes the
clinically negative neck is not dissected (usually when
Table 3 Suggested fractionation regimens for definitive treatment of oral cavity cancers
Author D (Gy) d (Gy) Fxs OTT (wks) Comment
Daly et al., [83] CTV1 66 2.2 30 6 With concurrent CT [83]
Yao et al., [82] 70 2 35 7 Sequential boost [82]
CTV2 54 1.8 30 6
Yao et al., [82] CTV3 54 1.8 30 6 [82]
Daly et al., [83] 50.1 1.67 30 6 [83]
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already known at the time of surgery-i.e. contralateral to
cN+). When dissected, indications for adjuvant treat-
ment include: pN > 1 (multiple pathologically involved
nodes/multiple levels); single node with extracapsular
extension; incomplete neck dissection (i.e. lack of level
IV dissection in patients with pathologically positive
level III); atypical node location (i.e. skip metastasis in
level III) (see Table 1) for dose level definitions).
Treatment of the neck can be unilateral for well latera-
lized lesions (i.e. buccal mucosa), in absence of cN2-N3
ipsilateral neck nodes [85] (see Table 6).
Oral tongue primaries carry a higher risk of contralat-
eral nodal disease than other oral cavity sites because of
the rich bilateral lymphatic drainage [86], therefore the
bilateral neck should be irradiated in all oral tongue can-
cer patients with involved ipsilateral nodes, especially in
high grade tumours or advanced T stages [82].
1. Oral tongue drainage is to ipsilateral level Ib and
level II, III and even level IV with an incidence of
skip metastasis of 10-15% [87]. An adequate elective
neck dissection for oral tongue SCC includes levels
Ib-IV. Five to ten percent of oral tongue cancers
have bilateral lymph node metastases [88,89].
2. For oral cavity SCC, the risk of positive nodes is
strictly correlated with the depth of primary
tumour invasion. Three to 9 mm tumours have a
44% risk of positive nodes and a 7% risk of local
recurrence; >9 mm thickness is associated with a
53% risk of subclinical nodes and 24% of local
recurrence [90,91].Table 4 Suggested fractionation regimens for postoperative s
Authors D (Gy) d (Gy) fxs OTT (wks)
Daly et al., [83] CTV2 66 2.2 30 6
Yao et al., [82] 64-66 2 32-33 6.5
60 2 30 6
63 1.8 30 6
CTV3 54 1.8 30 6
Daly et al., [83] 50.1 1.67 30 6
58.1 1.66 35 7
A surgery-to-RT interval of <6 weeks improves local-regional control.3. The floor of mouth and tip of the tongue drain to
levels Ia, Ib and II. The incidence of bilateral lymph
node involvement is relatively high because many
lesions are near or cross the midline [88,89].
4. Tumours of the buccal mucosa and hard palate not
exceeding midline drain to ipsilateral level Ib.
5. For well-lateralized lesions (at least 1.5 cm from
midline) only the ipsilateral neck should be
considered for treatment, especially in absence of
N2-N3 disease (except for oral tongue, see above).
6. In general, for cN0-1, elective nodal stations include
Ib-III with the exceptions of IIb (Table 6). The
addition of level Ia is for lesions of the floor of
mouth, oral tongue and lower gingiva. Adding level
IV is for lesions of the oral tongue, especially if in
the posterior 2/3.
7. The likelyhood that an oral cavity cancer involving
cervical lymph nodes of levels I to III would also
involve level IV is generally stated as 7% to 17%, and
the corresponding rate for level V is 0 to 6% [92,93];
8. For cN2-3, elective irradiation of level V is advised;
in case of extension to the tonsillar region, also
retropharyngeal nodes should be included.
Nasopharynx (NPX)
Standard treatment of nasopharyngeal carcinoma is
definitive RT ± CT.
Target definition remarks (Table 7)
1. CTV1 =GTV+ a margin of ≥ 5 mm should be given
circumferentially but can be 0–1 mm if anatomical
barriers are present. CT and MRI should be used toetting of oral cavity cancers
Comment
For positive margins or ECE
Sequential boost for extracapsular extension, positive or close margins,
bone or soft-tissue involvement.
Table 5 Anatomical landmarks in contouring various oral subsites
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Indeed, the clivus and nerves are best seen on MRI.
2. CTV 2 = whole NPX (Table 7) should be included in
high risk volume regardless T site [20,95,96]. Indeed
Sham observed that only 7% of patients had
involvement of one subsite regardless of T site [95].
The most outer boundary of CTV2 should be at
least 10 mm from the GTV.
Pathology remarks
Histological subtypes: the old WHO classification of
nasopharyngeal carcinomas [98], yet widely used in lit-
erature, should be replaced by the new one [99] in order
to avoid confounding factors:
WHO type 1 = keratinizing carcinoma
WHO type 2.1 = non keratinizing differentiated carcinoma
WHO type 2.2 = non keratinizing undifferentiated
carcinoma (with lymphoepitelioma variants)
WHO type 3 = basaloid SCC (a rarity)
While subsite only is not a predictor of treatment out-
come, histological subtypes are strongly variables by race
and strongly influence prognosis:Table 6 Guidelines for contouring neck levels [57]
cNo
Tongue Bilateral I-IV
Floor of mouth (well lateralized) Bilateral I-III
Hard palate Bilateral Ib, IIa, III, RP
Upper retromolar trigone Bilateral Ib, IIa, III, RP, ipsilateral Ia
Lower retromolar trigone Ipsilateral I, II, III
Buccal mucosa Ipsilateral Ib, IIa, IIIa) The asian population have a greater proportion of non
keratinizing tumours, up to 90% [100], while white
Caucasian race has a 60-70% rate of non keratinizing
tumours [101,102]. WHO Type I, II differentiated,
and II undifferentiated lesions have 41%, 56.1% and
68.5% 5-year survival rates, respectively [103].
b) Moreover WHO subtypes influence the risk of nodal
and distant metastases: Type 1 and 2 have a 60%
and 90% rate of nodal involvement respectively at
diagnosis; Type 1 and 2 have 5-8% and 30-40% dis-
tant metastases rate respectively at diagnosis [104].
c) Of note, the same radiation dose is prescribed for all
variants.
Dose/fractionation remarks
Table 8 shows the commonly used fractionation
regimens:
Primary-tumour contour
 Anatomic considerations (see also Table 7).1. NPX is usually divided into 3 subsites: a) postero-
superior wall: extends from the level of the junction ofIpsilateral N+ Comment
V if N2-3 Excluding IIb
IV and V if N2-3 Excluding IIb
Add bilateral Ia, IV, V if N2-3 Excluding IIb
Add contralateral Ia, bilateral IV and V Excluding IIb
Add ipsilateral IV, V Excluding IIb











Table 7 Standard anatomic limits of Nasopharynx
Anterior Posterior fourth to third of the nasal cavity and maxillary sinuses (to ensure pterygopalatine fossae coverage)
Posterior Anterior third of clivus (entire clivus if macroscopic infiltration), retrostyloid space
Lateral Lateral parts styloid processes (parapharyngeal space)
Cranial a. Skull base (foramen ovale and rotundum bilaterally must be included for all cases),
b. Inferior half sphenoid sinus – anterior half clivus (entire clivus and top sphenoid sinus if macroscopic infiltration or in T4 cases).
For lesions confined to the nasopharynx, the pituitary fossa can be excluded from the irradiated volume [97].
c. The cavernous sinus should be included in high risk patients (T3, T4, bulky disease involving the roof of the nasopharynx)
Caudal Soft palate
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including the Rosenmüller fossa; c) inferior wall:
consists of the superior surface of the soft palate.
2. The pharyngobasilar fascia is a robust fibrous
aponeurosis situated between the mucous and
muscular layers and covers the pharyngeal constrictor
muscles; it is bound inferiorly by the superior
pharyngeal constrictor, superiorly by the base skull,
and anteriorly by the posterior border of the medial
pterygoid laminae; it serves to attach the superior
pharyngeal constrictor muscle to the base of the skull
at both the basal part of the occipital bone and the
petrous portion of the temporal bone; the Eustachian
tubae generate an escape route for the tumour that
frequently exceeds this aponeurosis and reaches the
parapharyngeal and masticatory space.
 Neoplastic-behaviour considerations
1. Nasopharyngeal neoplasms typically arise near the
Rosenmuller fossa.
2. The natural local growth follow four directions











poni ei. nasal cavity;
ii. masticatory space via pterigomaxillary fissure;Suggested fractionation regimens for NPX
D (Gy) d (Gy)
CTV1 70 2
al., 2009 69.96 2.12
al., 2009 67.5 2.25
t al., 2010 66-69.63 2.2-2.11
CTV2 63 1.8
al., 2009 59.4 1.8
al., 2009 54-60 1.8-2
CTV3 58.1 1.66
56.1 1.7
al., 2009 50.4 1.8
al., 2009 48 1.6
t al., 2010 51 1.7iii. carotid canal via anterior foramen lacerous;
iv. intracranial (medial cranial fossa) via foramen
rotundum;
v. orbital cavity and cranial anterior fossa via
superior orbitae fissure.
b. Lateral:
i. masticatory space via Eustachian tubae,
ii. posterior cranial fossa via giugular foramen
and giugular internal vein;
iii. cavernous sinus via mandibular nerve and
foramen ovale.
c. Posterior : prevertebral muscles and vertebrae via
prevertebral fascia;
d. Inferior: oropharynx Therapeutic considerations1. Induction CT is sometimes used for neoadjuvant
purposes to shrink and downsize the tumour
especially when it is abutting OARs whose tolerance
is inferior to the prescribed GTV dose (i.e.
brainstem). In this case, the pre-induction target
should receive full dose [29,109] (Figure 2), but the
dose to the original site of disease is often limited tofxs OTT (wks) Comment
35 7
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pathways) while the residual tumour is prescribed/
delivered a full dose.
The patient should be simulated supine with the head
hyperextended [110] to provide adequate separation be-
tween the primary lesion/retropharyngeal lymph node
and the upper neck field and to avert eyes from the pri-
mary volume, or in neutral position.
Lymphnode-level contour
 Anatomic considerations.
There are three distinct pathways of lymphatic
drainage from the nasopharynx: i. Postero-inferiorly
to the retropharyngeal nodes (including the node of
Rouviere); ii. Directly to superior deep cervical
nodes; iii. Laterally to mastoid and spinal accessory
nodes (level V).
The initial lymphatics (including capillary network
and precollectors) arise in the wall of the nasal
fossae and the nasopharynx.The lymphatic collectors run into the parapharyngeal
space to the lateral pharyngeal and retropharyngeal
lymph nodes. They run through the lateral wall of the
nasopharynx and form two lymph collectors (lateral and
medial) that descend laterally to the pharyngeal wall in
the parapharyngeal fat tissue:
i. the lateral one is situated on the lateral side of the
external carotid artery;
ii. the medial is located one medially along the external
carotid artery.
The lateral group provides lymphatic drainage from
the lateral walls (including Rosenmuller Fossa) directly
into deep nodes of the posterior triangle (upper level V)
while the medial trunk drains to the superior deep cer-
vical nodes (levels II and III) [111,112].
 Neoplastic-behaviour considerationsTable 9 Guidelines for contouring bilateral neck levels
(negative on imaging)




IV, Vb Low Higher risk when level III is
clinically involved
IB Very Low Omit or include only in
case of neck node positivity1. The primary lymphatic drainage of
nasopharyngeal carcinoma is to retropharyngeal,
II and Va nodal levels. Setting the cranial border
of level IIb node at the skull base should be
considered when delineating nodal target
volume [113].
2. The secondary lymphatic drainage is to levels III
and Vb [114].
3. Level IV is involved in 10% of the cases [115].
4. Level Ib is rarely involved; it has to be included
only in case of clinical adenopathy evidence
[115]. It should be noted, however, that theposterior part of level Ib was routinely irradiated
in the old days [59].
5. Lymphatic drainage is bilateral. Therefore, both
sides of the neck are at risk [41] (Table 9).
6. Retropharyngeal nodes (top of C1 to bottom of
C2, sometimes C3 [108,116]) should be always
included in the CTV2.Few studies have investigated the option to withhold
elective treatment for cN0 patients. One of them found a
high regional salvage rate with either surgery or RT [117].
It should be noted, however, that patients with residual
persistent disease in the neck or who fail in the neck have
a higher risk of distant metastases than patients who do
not fail in the neck. Therefore, comprehensive neck irradi-
ation (including levels II-V) is always advocated for NP.
Oropharynx
The oropharynx is usually divided into 4 sub-sites: ton-
sil, base of tongue, pharyngeal walls and soft palate.
While sub-site only is not a predictor of treatment out-
come, HPV related tumours, with a more favourable
prognosis compared to their alcohol and tobacco coun-
terparts, usually originate from the base of tongue or
tonsils. Currently there are no practical implications or
differences between HPV positive and negative tumours.
Dose/fractionation remarks
Table 10 shows the common fractionation regimen.
Primary-tumour contour
 Historical perspective:1. In the standard 3-field era, the whole oropharynx was
included in the low dose region and the primary
tumour boosted to the final dose. Whether the
whole oropharynx should be included in the low risk
region is somewhat controversial and no definitive
recommendations can be made. However, some
Authors, especially in presence of HPV related tumours
(that seem to have a lower risk of field cancerization)
tend to limit the low risk volume (CTV3) to the
sub-site involved or, at most, the adjacent one (i.e. in
Table 10 Suggested fractionation regimen for oropharyngeal cancer
Authors D (Gy) d (Gy) Fxs OTT (wks) Comment
CTV1 70 2 35 7
Eisbruch [17] 66 2.2 30 6 T1-2 in absence of conc chemo (RTOG 00–22)
Sanghera [118] 55 2.75 20 4.5 Retrospective analysis
CTV2 63 1.8 30 6
Eisbruch [17] 60 2 30 6 T1-2 in absence of conc chemo (RTOG 00–22)
CTV3 58.1 1.66 35 7
Eisbruch [17] 54 1.8 30 6 T1-2 in absence of conc chemo (RTOG 00–22)
Sanghera [118] 41.25 2.75 15 3
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volved tonsil and the tongue base but not the contralat-
eral tonsil).
2. In the old days, a typical initial field for a tonsillar
tumour included the whole pterygoid plates up to
the base of skull; therefore it is recommended that
CTV3 cover the whole pterygoids as well. Clinical and anatomical considerations1. Trismus is a surrogate of medial pterygoid muscle
invasion and in this case a generous margin along
with the medial pterygoid muscle should be
contoured during CTV1 definition;
2. The anterior extent of the GTV in the tongue base
is best evaluated via contrasted CT or even better
with MRI; due to subclinical anterior extension,
especially for infiltrative primary tongue base
tumours, a generous margin (1.5-2 cm) around both
CTV1 and CTV3 should be added anteriorly;
3. Patients with dentures that are likely to create visual
artefacts should be positioned with the head in a
different position (more flexed or extended);
moreover, the location of the primary tumour
should be driven by a different study, i.e. MRI;
4. After primary tumour (surgical) removal, unless the
original location of the primary is clearly available
and visible on a dedicated study, the whole sub-site
should be part of CTV;
5. Parapharyngeal space is a locus minoris resistentiae
and needs to be included in the CTV in the case of
possible/suspected local extension and/or retro/
parapharyngeal node involvement (Figure 3).
Lymphnode-level contour
1. The primary lymphatic drainage of oropharyngeal
SCC is to levels II, III and retropharyngeal nodes.
Bilateral spread is fairly common for lesions that
approach midline (such as in the case of the tongue
base and soft palate), while it is relatively rare forwell lateralized lesions (at least 1.5 cm from midline
as in the case of tonsil primaries) in absence of
multiple or large (>3 cm) lymph nodes; in addition,
lesions arising or involving the soft palate have
an increased risk of level I (Ib) involvement;
2. When the primary tumour is well lateralized
(e.g. tonsil) and the ipsilateral neck shows limited
involvement (N0-1, questionable N2a), contralateral
neck coverage can be omitted;
3. Some Authors [59,119] would limit level IB coverage
to its most posterior part. The anterior extent of the
contour of level IB when included in CTV3 would
stop at the anterior extent of the submandibular
gland and, therefore, exclude the triangular fat space
lateral to the deep extrinsic muscles of the tongue.
4. Retropharyngeal nodes (top of C1 to bottom of C2,
sometimes C3) should be always included in the
CTV3 unless suspicious (>5 mm).
5. In case of suspicious neck nodes (as previously
defined) and lymph node enlargement in other sites
than ipsilateral levels II and III, the suspicious
finding and not the whole level should be contoured
as CTV2.
6. Table 11 provides some indications for contouring
ipsilateral and contralateral neck levels that are
negative at imaging.
Hypopharynx
SCC of the hypopharynx is usually diagnosed at a later/ad-
vanced stage. Moreover, due to local (submucosal) invasion,
it is usually considered more aggressive/less radioresponsive
than its laryngeal counterpart. Concomitant CT is usually
indicated for T3-4 or anyT N+ [120-123], but some Au-
thors in monoinstitutional experience [124,125] claim the
use of concomitant CT also for earlier T stage (T2) lesions
even if the only two large randomized trials specifically ad-
dressing the hypopharyngeal cancer subset [126,127] with
few T2 patients included, used sequential or alternate ChT
and RT and not concomitant treatments. In patient unfit
for standard concomitant CT, induction CT or the con-
comitant association with Erbitux can be considered [11].
Figure 3 Laryngeal anatomy.
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toxicities, hypofracionation delivered with SIB is not
recommended [122,128].Target definition remarks
CTV2. After surgery, CTV2 would include the whole
laryngo-pharynx bed with particular attention to the
cranial and caudal extent of resection (i.e. cervicalTable 11 guidelines for contouring ipsilateral and
contralateral neck levels negative at imaging
Side Level Risk Remarks
Ipsilateral Ib Low CTV3 Higher risk for soft palate/oral
cavity involvement or multiple
positive neck levels-CTV2
II-III High CTV2 Lower risk when the whole
neck is negative (cN0)-CTV3








Omit Higher if the contralateral II-III
lymph node level is clinically
positive or the soft palate
is involved
II-III Low CTV3 Higher risk if the contralateral
level IB is clinically positive




Omit Omit unless suspicious nodes





 In the old days, the lower extent of tumour coverage
(cricoid cartilage) needed a low neck junction that
was particularly troublesome in patients with a
short neck; nowadays with IMRT, the issue about
adequate coverage of the caudal part of the CTV is
overcome [128].
 Clinical and anatomical considerations
 The hypopharynx consists of the pyriform sinuses,
postcricoid region and posterior pharyngeal wall.
The anatomic boundaries of the hypopharynx
include the ariepiglottic folds (superiorly), the
cricoid cartilage (inferiorly), the prevertebral fascia
(posteriorly) and the larynx (anteriorly).
 Unlike the larynx, the hypopharynx has no clear
barriers to cancer extension. The boundary
between the oropharynx and hypopharynx is
theoretical and the boundaries between different
subregions are more anatomical landmarks that
real barriers.
 Because submucosal extensions are hardly visible,
it is preferable to have larger volumes to reduce
the risk of recurrence. Therefore, CTV2 would
encompass 1–1.5 cm of normal mucosa cranial
and caudal to CTV1 [129].
Table 12 Suggested fractionation regimens for hypo-








CTV1 70 2 35 7




69.6 2.11 33 6.5
Miah et al. [123] 63 2.25 28 5.6 Arm 1 (DL1)
67.2 2.4 28 5.6 Arm 2 (DL2)
CTV2 63 1.8 35 7
Lee et al. [122] 59.5 1.7 35 7
CTV3 58.1 1.66 35 7
Lee et al. [122] 56.0 1.6 35 6.5
Studer et al.
[121]
54 1.64 33 6.5
Miah et al. [123] 51.8 1.85 28 5.5 Acute Grade 3 (G3)
dysphagia was higher
in DL2 (87% DL2 vs.
59% DL1)
56 2 28 5.5
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with a dedicated esophagoscopy.
 Especially for lesions involving the medial wall of the
pyriform sinus, the posterior part of the larynx
(arytenoids and interarytenoid region) should be
part of the CTV1 as well.
 Involvement and violation of the prevertebral fascia
can be appreciated clinically (tumour fixation) and
on imaging (MRI); in case of prevertebral space
invasion, the lesion becomes unresectable and the
margins for cranio-caudal microscopic tumor spread
would be wider than usual.
 Indications to boost the stomal region after major
surgery basically duplicate those for laryngeal
primaries.
Lymphnode-level contour
1. Tumours of the hypopharynx have a high tendency
to spread to lymph nodes.
2. The risk of subclinical disease in lymph nodes is not
strictly correlated to the stage of the primary
tumour.
3. Stations at risk are reported in Table 13 [57,130].
4. Lymph node level VI has to be encompassed if
oesophageal extension is present.
5. Ipsilateral retrostyloid lymph nodes should be




Table 12 reports the most used fractionation schemes
for laryngeal cancer. The standard dose for T1N0 of the
glottic larynx is 66 Gy /33 fxs/6.5 weeks. For T1 glottic
lesions, the d./f. used within 3DCRT has been up to
3.43 Gy [131] (Total dose 55Gy/16 fractions); there is
limited experience with IMRT for this fractionation, andTable 13 Guidelines for contouring neck levels when















nodes need to be included if










N+ I-V, RP bilateral,
VI ipsilateral
Ipsilateral retrostyloid lymph
nodes need to be included if
clinical or radiological level II
involvement is present.thus the recommendation is to limit the d./f. to 2.25 Gy
to 56.25–63 Gy [132] in the context of IMRT. For T2
glottic lesions, RTOG 9512 found only trend in favour
of hyperfractionation over standard fractionation [133].
For more advanced lesions (T3-4) of the larynx,
there are consolidated data on the benefit of altered
fractionation in terms of both local control and sur-
vival; the best outcome is reached with hyperfractiona-
tion [134]. However, hyperfractionation hardly fits
into an IMRT technique for reasons that have been
previously discussed; moreover with the advent of
ChT, RT alone is rarely used for T3-4 lesions.
In the postoperative setting, the most used schedule is:
66 Gy in 33 fractions (2 Gy daily) to CTV1, 59.4 Gy in
33 fractions (1.8 Gy daily) to CTV2 (optional) and
54,12/56,1 in 33 fractions (1.64-1.7 Gy daily) to CTV3.
After subtotal laryngectomies (horizontal supraglottic
laryngectomy-HSL, near total laryngectomy, hemilaryn-
gectomy) there is the concern that adjuvant RT (±ChT)
may jeopardize the functional outcome of the residual or
surgically spared larynx [135]. For example, after HSL
(horizontal supraglottic laryngectomy), it has been found
that 60 Gy radiation significantly increases the risk of
laryngeal edema (over 50 Gy) [136]. Therefore, unless spe-
cifically indicated (positive resection margins) and after
careful discussion with the patient, the dose to the larynx
should be kept within 50 Gy (see also below) [137,138].Primary-tumour contour
The larynx is divided into three anatomic regions: Supra-
glottis — suprahyoid epiglottis, infrahyoid epiglottis,
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tricular bands (false cords). Glottis — true vocal cords,
including anterior and posterior commissures. Subglottis —
subglottis, extending from lower boundary of the glottis to
the lower margin of the cricoid cartilage [139].
Definitive treatments
 Anatomical considerations1. Target volumes are defined according to the
pathways of cancer extension in the larynx
(Figure 3). Cancer of the larynx mainly spreads by
direct extension (following the line of least
resistance), prior to lymphatic spread and more
rarely follows the vascular and neurological routes.
The main way of diffusion of laryngeal cancer is to
para-glottic and to the pre-epiglottic spaces through
the anterior commissure, the thyro-epiglottic and
thyro-arytenoid ligaments (upper and lower), the
ligament and crico-thyroid membrane, the perfora-
tions of the sub-hyoid epiglottis, the bottom of the
ventricle and laterally through the thyroid cartilage.
These two spaces also play an important role for the
T classification, as neoplastic invasion of these spaces
upstages laryngeal cancer to T3.
Therefore, if these structures are directly
encompassed by GTV, CTV1 should include also
pre-epiglottic and para-glottic space. Historical perspective1. In the 3DCRT era the whole larynx or the majority
of it was included in the CTV1; nowadays there is
the tendency to include in the CTV1 only the
expanded GTV; however, careful considerations
about the depth of invasion, the natural history
of disease, the presence/absence of anatomical
barriers (i.e. continuity between pre-epiglottic and
para-glottic spaces (Figure 3) and the quality of the
imaging should always be taken into consideration;
the use of anatomic compartments to define CTV
boundaries is more adequate than the use of any
arbitrary uniform expansion around the GTV, unless
such boundaries are not well-defined, such as the
anterior boundary in case of base of the tongue
involvement [50]. Thus, the CTV1 corresponds to
the GTV plus a margin of 5 mm to 1 cm or more,
depending on the ways of diffusion or anatomical
barriers (i.e. supraglottic tumours extending to the
aryepiglottic folds will be outlined extending the
superior margin of the CTV to 2 cm above the
GTV; in case of infiltration of the base of tongue,
a structure that does not present anatomicalbarriers, a margin of 1.5-2 cm is appropriate) and
should not be modified according to a possible re-
sponse to induction ChT.[140]. In correspondence of
anatomical barriers GTV to CTV expansion should
not exceed those structures (eg, prevertebral fascia,
bone). In case of doubt of submucosal extension, it is
better to enlarge the volumes to reduce the risk of
recurrence.
2. The level of complexity required for the irradiation of
laryngeal cancer is highly variable and IMRT may
provide distinct advantages over 3DCRT in sparing
OARs (parotids, especially when level IIb is part of the
target, carotids for early stage lesions) and covering
the target (avoiding field junctions and irradiating the
subglottis especially in patients with a ‘short’ neck’).
Though there are several dosimetric and even
preliminary clinical experience with IMRT for T1-2
glottic cancers [141,142] or for locoregionally ad-
vanced glottic and supraglottic cancers [121-123], the
clinical benefits of IMRT are usually speculative and
the standard of care remains 3DCRT.
Table 14 provides guidelines for contouring primary
tumor CTVs on planning imaging:
Postoperative treatments
In the postoperative setting, features that are usually
considered predictors of local relapse are: i. close or
positive margins; ii. pT4; iii. extracapsular extension of
the neck nodes. Other features (i.e. perineural spread)
are less recognized and need to be considered on a case-
to-case basis. In order to outline postoperative volumes,
pre-surgery imaging studies and operative note(s) should
be carefully reviewed. Moreover, the natural history of
the disease plays also an important role.
In case of subglottic or soft tissue extension, the re-
gion of the stoma should be included in CTV2, while for
upward lesions (i.e. lesions with significant anterior ex-
tension in the pre-epiglottic space) the base of tongue
needs to be included in CTV2.
After subtotal laryngectomy, the decision to include the
larynx within the low dose level (even in absence of high
risk features), simply because it has been part of the opera-
tive bed, is controversial [135]. However, regardless whether
the larynx is included or not, careful planning should avoid
unnecessary overdosing of the larynx (>50 Gy) in absence
of specific indication (e.g. if the decision to irradiate a re-
moved level II node with extracapsular extension is made,
the larynx should not receive a dose higher than 50 Gy
even though the lymph-nodal area at risk needed a dose
higher than 60 Gy). For high risk patients (R1 and pT4)
CTV1 should include the whole remnant larynx with cra-
nial and caudal extent of resection (e.g. subglottic exten-
sion) and the site of dissected positive lymph-nodes.
Table 14 Guidelines for contouring larynx (according to subsites)
Supraglottic
larynx
Superior limit Inferior limit Ipsilateral limit Contralateral limit Anterior limit Posterior
limit
CTV 1 GTV + 0.5-1 cm
margin
idem Idem idem Idem idem
































CTV 3 Optional (add
margin from
CTV 2)
Idem Idem Idem Idem idem
Glottic larynx
CTV1 GTV + 0.5-1 cm
margin












muscle laterally to thyroid
cartilage, cricoid cartilage























CTV 3 Optional (add
margin from
CTV 2)
Idem Idem Idem Idem idem
Subglottic larynx
CTV 1 GTV + 0.5-1 cm
margin
idem Idem idem idem idem



































CTV 3 Optional (add
margin from CTV 2)
Idem Idem Idem Idem idem
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Anatomical considerations.
Supraglottic larynx
The lymphatic drainage terminates in the ipsilateral level
II nodes while a second component extends lateral and
drains into nodes located at the junction of Levels II and
III. There is occasionally a third component that drains
into the nodes located in Level III nodes.
Tumours involving the supraglottic larynx are at risk of
crossing lymphatic drainage. The risk of palpable lymph
nodes at presentation is higher for epi-laryngeal tumours
than for the rest of supraglottic one [143].
Glottic larynx
The true vocal cords (TVC) form a natural barrier be-
tween the supraglottic and infraglottic larynx due to itspaucity of lymphatic draining. At any rate, the lymphatic
drainage of sovraglottic or subglottic larynx can be in-
volved by advanced TVC carcinoma.
Subglottic larynx
Lymphatics from the subglottic larynx drain to the mid
and lower jugular lymph nodes (levels III and IV) and to
the prelaryngeal (cricothyroid or Delphian) node. Subse-
quently, the pretracheal and paratracheal lymph nodes
can be involved [144].
Tables 15 and 16 provide guidelines for contouring
neck levels either in the case of negative or positive
nodes on the imaging:
Historical perspectives
1. For T2N0 of the glottis, the standard recommendation
is to treat the larynx only, but the actual results are













Supraglottic T1-2 II-III (bil) IV (bil),










Levels II and III if
supragl extLevels III
and IV if subgl ext
(see text)
T3-4 II-III (bil) IV (bil), VI
VII only if
subGL ext
RP only if ext
to pharynx
Subglottic T1-2 III-IV (bil) VII optional
T3-4 II-IV (bil) VI, VII, RP only
if ext to
pharynx














II-III (bil) IV bilat, V (on the side
of positive neck)









II-IV (bil) IIb if IIa positive, VI,
Supraglottic/ V (on the side of
positive neck),
Subglottic IB only on the side
level II is pos*,
VII only if subGL ext
RP only if ext to
pharynx
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irradiate with two lateral opposing fields. Authors
showed that portions of the neck lymphatic chain
where inadvertently treated [59,133]. Therefore, it is
advisable, in common practice, to irradiate levels
II-III and III-IV especially when lesions extend into the
supra or sub-glottis.
2. For primary lesions with subglottic involvement and
clinically detectable lower neck nodes, the upper
mediastinum (down to the level of the carina) was
prophylactically covered with AP/PA fields.
Therefore, inclusion of level VII in the CTV3 is
advised in case of subglottic extension with
significant and lower neck disease.
3. In the case of No, level IIb should not be irradiated.
Planning remarks
1. In case of suspicious neck nodes (as previously
defined) it is unclear whether only the suspicious
finding or the whole level should be included in the
CTV2. For nodes belonging to lymph node stations
different from ipsilateral levels II and III, the
suspicious finding and not the whole level should be
contoured as CTV2.
2. For lymph nodes that show gross extracapsular
disease, a margin of 5[41]-10[53]mm aroundthe visible GTV is usually added; in case of
muscular infiltration by a pathological lymph
node (i.e. sternocleidomastoid muscle), it is
recommended to include at least the portion of
the muscle surrounding the node [47]. Similarly,
it would be appropriate to include the whole
muscle (i.e. sternocleidomastoid muscle) in the
lowest dose level when grossly infiltrated at
some level.
3. After surgical removal of a lymph-node with
extracapsular extension, the initial location of
the node needs to be identified; careful planning
should avoid underdosing of the surgical scar close
to the pre-surgery location of the node (sometimes
3–5 mm skin bolus is necessary).
4. Subglottic cancer, transglottic cancer, and glottic
cancer with subglottic extension have a higher risk
of para-tracheal nodes involvement; for T > 2 even
in N0 patients, this level should be included in
CTV3 [57,145].
5. Ipsilateral Ib nodal level and parapharyngeal space
extending to retrostyloid space should be included if
level II nodes are positive.
Paranasal sinuses and nasal cavity
Target definition remarks
RT may be indicated as postoperative (i.e. adenocar-
cinomas) or definitive treatment with or without con-
comitant CT. Whereas the definitive treatment leads to
the irradiation of the usual 3 CTVs as described in the
general part, the previous surgical approach (midfacial
degloving, lateral rhinotomy, craniofacial, or endoscopic)
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Detailed description of the surgical procedure and path-
ology report is mandatory. In the postoperative setting,
there is no identifiable GTV and thus CTV1 is not avail-
able. CTV is represented by all areas at risk of contain-
ing residual microscopic disease and the choice between
HR and LR depends on the risk for each sub-volume.
Dose/fractionation remarks
Table 17 shows the commonly used fractionation
regimens:
Primary-tumour contour
Table 18 describes the limits of the CTV2 for eth-
moid and maxillary regions, according the suggestions
of Stratt et al. [149].
Planning remarks
1. In regions where the GTV is flanked by anatomic
barriers (i.e. intact bone), no margin is usually added.
In regions where GTV involves compartments
enclosed by bone (i.e. maxillary sinus), the whole
compartment is contoured as CTV1.
2. When the tumour is in proximity of radiologically
defined spaces known to poorly resist to invasion
(i.e. masticator or para-pharyngeal spaces) either
the entire space or at least part of it should be
contoured as CTV2/3. The former is usually
reserved for the part close/next to the tumour
while the latter for the remaining part.
3. Similarly, when the tumour is abutting the medial wall
of the orbit or there is minimal orbital invasion, the
medial part (including the rectus medialis muscle) of
the orbit has to be included into the CTV2/3.
4. The choice of the regions at risk for microscopic
disease depends on the location of the primary
tumour, its extension/stage, and pathology. In
general, the palate, alveolar ridge, nasal cavity,
and the nasopharynx are included in the CTV2/3 in
case of maxillary sinus tumours, and the medial
orbit in maxillary/ethmoid-sinus cancers. The
pterygopalatine fossa and infratemporal fossa,
frequently at risk of subclinical disease, are included
in the CTV2/LR. Superior lesions require CTV
extension to the sphenoid sinus and foramen
rotundum at the base of skull to accommodate
potential involvement of the maxillary nerve.
5. If MRI suggests neural involvement, the CTV2/3
should be extended to include the cavernous sinus. For
lesions in the upper nasal cavity and ethmoid sinuses,
the cribriform plate and a rim of the frontal lobe are
included in the CTV2/LR. The anterior cranial fossa is
included in case of intracranial extension [16].6. As a general rule, after induction CT, the original
location of the tumour (and not the residual)
represents the CTV1.
7. In the postoperative setting, CTV2 consists of the
resection cavity plus a variable margin according
to the principles of a “compartment-related CTV”
as described above. All surgically violated regions
should be included in the lowest dose level
CTV.
8. In case of adenoid cystic carcinoma, attention
should be paid to the neural spread and, hence, RT
volumes must encompass the afferent and efferent
local nerves up to the skull base.
9. Esthesioneuroblastomas arise in the superior nasal
cavity and, even at early stages, tend to invade the
cribriform plate and anterior cranial fossa, and
therefore, these regions should be encompassed in
the target volume.
Lymphnode-level contour
1. Lymph node metastases are unusual, thus elective
treatment of the neck is not mandatory (excluded
in the cases of esthesioneuroblastomas, high-grade/
high-stage SCC or whenever the next anatomical
regions (e.g. nasopharynx, cheek, gingiva or alveolus)
are involved.
2. Lymphatic drainage from the paranasal sinuses is to
the retropharyngeal, submandibular, and
jugodigastric nodes [57]. Cervical metastases are
below 10% at presentation thus not justifying
elective dissection. For the same reason lymphnodes
are usually not included in any CTV unless involved
or at risk. The risk of involvement usually depends
on the location of the primary tumour and the
pathology. Adenocarcinomas and sinonasal
undifferentiated cancers (SNUC) rarely spread to
lymph nodes; some Authors claim prophylactic neck
treatment for esthesioneuroblastomas [150] or SCC
of the maxillary sinus [151,152].
3. Once prophylactic neck treatment is indicated, the side
of the neck and the levels to be contoured depend on
both the location of the tumour and its pathology. For
maxillary sinus, levels IB and II represent the first
echelon; for esthesioneuroblastomas, a comprehensive
neck irradiation (levels IB-V) is the rule. Bilateral
retropharyngeal nodes irradiation should be
considered.
Planning remarks
1. After CTV to PTV expansion, overlap between PTV
and OAR is frequent and optimal target coverage is
often challenging.
Table 17 Suggested fractionation regimens for para-nasal sinus and nasal cavity
Definitive D (Gy) d (Gy) fxs OTT (wks) Comment
Daly [146] GTV 69.96 2.12 33 6.5
CTV1 70 2 35 7
Wiegner [147] 66 2.2 33 6.5
CTV2 63 1.8 35 7
Daly [146] 59.4 1.8 33 6.5
CTV3 58.1 1.66 35 7
Daly [146] 54.12 1.64 33 6.5
Postoperative setting
CTV2 63 1.8 35 7
Hoppe 2008 [148] 60-66 2-2.2 30-33 6 Especially for adenocarcinoma
CTV3 58.1 1.66 35 7
Hoppe [148] 54-54.12 1.8-1.64 30-33 6
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of late toxicity >10% on selected OARs as brain,
brainstem, chiasm and optic nerves.In the planning
process, any attempt should be made to maintain
coverage of CTV1 while compromising the
coverage of PTV in order to allow minor variations
in selected OAR irradiation (i.e. V95% of CTV1
is >95% while PTV1 coverage is 93% and optic
nerve Dmax is 59.9 Gy).
3. Proton Beam Therapy has shown good results and
acceptable toxicity especially in locally advanced
inoperable paranasal tumours [153,154].
Salivary glands
Target definition remarks
Salivary gland tumours are usually treated with sur-
gery. Curative RT alone is an option (even if the odds’
local control is relatively low) for patients with technic-
ally unresectable disease or inoperable for medical rea-
sons or who refuse surgery.
Risk factors that support postoperative RT include T3/
T4 disease and or any of the following [155,156]:
 Incomplete or close resection marginsTable 18 Suggested CTV2 for ethmoid and maxillary sites
Superior Inferior
Ethmoid Cribriform plate should be
included.
The inferior turbinate; In the case
that the inferior border of the GTV
allows a 10-mm margin around the
original disease, the entire hard pal-
ate does not need to be included.
In the case it was been
resected the margin should
encompass all the initial
GTV including the dura or
the dural graft.
Maxillary The inferior border of the maxilla
and the hard palate but should
encompass a 10-mm margin





Salivary gland tumours include a variety of both benign
and malignant tumours that can involve both minor and
major salivary glands. In major salivary glands the most
frequent benign tumour is pleomorphic adenoma, whereas
the most frequent malignant hystology is mucoepidermoid
carcinoma; adenoid cystic carcinoma is the most frequent
malignant tumour in minor salivary glands. Diagnosis is
often difficult and experienced pathologist is needed
to interpret fine needle aspiration cytology. Table 19
summarizes the most important pathology variants
and the role of RT:
External beam RT with photons is rarely a curative op-
tion since local control in malignant salivary gland tu-
mours is dose dependent. Considering that high doses
are needed to achieve local control, most malignant sal-
ivary gland tumours would probably benefit from the
use of particle therapy. However, although locoregional
control after neutron therapy seems to be higher thanLateral Posterior
The nasal cavity, ethmoid
sinuses, and the ipsilateral
maxillary sinus and when
indicated the volume should
extend to the rectus muscle.
Include the sphenoid sinus. The
retropharyngeal lymph nodes
should be encompasses if the
tumour extended close to the
nasopharynx or if there are
metastatic neck nodes from an
ethmoidal carcinoma.
Medial aspect should be the
nasal septum, unless violation of
midline structures occurs.
The pterygopalatine and the
infratemporal fossa should be
included, paying special attention
to encompass the masticator space
and the infraorbital fissure.
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served while OS was equal. Promising results were
found in a dose escalation study in locally advanced ade-
noid cystic carcinoma. Patients were treated with stereo-
tactically guided or photon IMRT (45-54Gy) and a
carbon ion boost of 18 GyE. The results are similar to
those obtained with neutrons alone but with lower late
toxicity profile [157].
Dose/fractionation remarks
Table 20 summarizes the most commonly used post-
operative fractionation regimens:
Primary tumour contour
1. A bolus over the scar region is indicated in the case
of skin invasion, for superficially located tumours of
the parotid or submandibular glands and/or in case
of tumour spillage/ capsular rupture.
2. Adenoid cystic tumours have the distinct
propensity for perineural infiltration (facial,
trigeminal, hypoglossal, lingual nerve) and
skull base involvement; in case of ‘named’ nerve
invasion, CTV3 must track the course of the nerve
as back as to its entry in the skull (base of skull).
The addition of concomitant adjuvant CT is still
investigational.
3. The CTV is a function of the location of the tumour
(Table 21), its extension and histological risk
factors; for low grade tumours, only the tumour
site (i.e. parotid bed) is at risk; for high grade
tumours, CTV2 includes the initial site of
disease, while CTV3 should cover the whole
surgical bed.
4. For parotid gland tumours, a document online
describes target volume definition of the parotid bed
and indications for ipsilateral neck irradiation for
patients entering the COSTAR trial (COchlear
Sparing Therapy And Conventional Radiation: A
Multicentre Randomised Study Of Cochlear Sparing
Intensity Modulated RT Versus Conventional RT In
Patients With Parotid Tumours)
http://aktinotherapeutis.gr/wp-content/uploads/doc-
tors/COSTAR_Outlining_Guidelines.pdf
4. The parotid gland extends from the zygomatic arch
superiorly to beyond the lower border of the
mandible inferiorly. Posteriorly, the gland dips in the
space between the mandible and the mastoid, with
the adjoining external auditory meatus intimately
surrounded by the gland in its free borders, that is,
anteriorly and inferiorly. On a deeper plane, the
parotid is related to the styloid process and themuscles connected to it (Figure 4). Local infiltration
of tissues adjacent to the parotid gland is the main
pattern of spread. This follows the anatomical
borders of the parotid gland and in cases of
perineural invasion, the facial nerve to the
stylomastoid foramina.
5. CTV2 for parotid tumours includes: the parotid
bed and any adjacent tissues at risk of
microscopic spread.
a. Areas at risk of soft tissue extension are:
infratemporal fossa, parapharyngeal space,
masseter and digastric muscle, skin.
b. Bone infiltration-at risk areas include: lateral part
of the floor of middle cranial fossa, neck of man-
dible, external auditory meatus, inferior surface of
styloid process.
Lymphnode-level contour
1. Elective nodal irradiation should be considered in
any of the following [158]:
a. High grade tumours
b. T3/T4 stage
c. Histological subtype
i. Squamous cell carcinomas
ii. Adenocarcinomas
iii. Undifferentiated carcinomas,
iv. High grade mucoepidermoid carcinomas
v. Salivary duct carcinomas
2. In case of risk of subclinical disease, if the primary
tumour is dissected, the lymph node levels at risk
should be dissected as well (surgical/pathological
staging of the neck is usually preferred to elective
treatment of undissected neck).
3. After surgery, planning should avoid underdosing of
the skin especially when capsular rupture is present
(bolus over the scar).
4. Levels Ib, IIa IIb, RP ipsilateral nodal stations
(commonly in tumor bed) should be included in
CTV2 for parotid tumors.
5. Levels III, IV and V ipsilateral nodal stations should be
included in CTV3 for parotid tumors when high
grade features are present, T3-T4, and the histological
type listed in point 1 if neck is undissected [159,160].
6. There is no indication for bilateral elective neck
treatment.Neck metastases from unknown primary (cTx)
General remarks
Metastatic cervical nodes of unknown primary origin
represent a very heterogeneous entity. Squamous cell car-
cinoma is the more frequent histological type, followed by
adenocarcinoma and undifferentiated carcinoma.
Table 19 Summary of the most important pathology
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Table 21 Suggested volumes (surgical bed) at high risk
Site Anterior Lateral Medial Posterior










Follow clips if leaved by surgeon otherwise
and use the contralateral submandibular
gland as a guide.
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oma (eg melanoma, lymphoma, adenocarcinoma), a pri-
mary arising in the chest, thyroid or salivary gland cancer
should be suspected and treatment should be planned ac-
cordingly (the following guidelines would not apply).
Here we consider only SCC or undifferentiated
carcinoma.
There are some correlations between the location of
the node and the primary site:
1. superficial parotid: skin;
2. level Ib: oral cavity;
3. level Va: NPC;
4. level IV: chest (or abdomen)
More than 50% of primaries are discovered by physical
examination and assessment under anaesthesia con-
ducted by experienced ENTs (this data refers to pre-PET
era) [161]; 50-80% of primaries are found in the oro-
pharynx; there is a strong correlation between HPV, cys-
tic nodes and oropharyngeal primary [162], but up toTable 20 Commonly used postoperative regimens
D (Gy) d (Gy) fxs OTT (wks) Comment
CTV2 66 2 33 6.5 [155]
63 1.8 35 7
CTV3 60 2 30 6 [155]
54 1.8 30 6
58.1 1.66 35 7
59.4 1.8 33 6.5
In general the radiosensitivity of salivary gland tumours depends on their
pathology; doses for SCC are similar to SCC of other districts; for adenoid
cystic doses in the order of 66 Gy and 60 Gy (at 2 Gy per fr) are
recommended for CTV2 and CTV3, respectively [155] A dose of 60 Gy for
postoperative treatment of high grade tumours has been suggested also by
Chen et al. [158].25% of patients may have primary disease below the
clavicles (lungs). EBV testing may help determine possible
primary location. There is no advantage for repeated
Direct Laryngoscopy if negative initially [163].
More than FNA (e.g. incisional/excisional biopsy) is con-
sidered ‘neck violation’ and should be avoided. Injudicious
removal of a metastatic node causes surgical scarring which
may prevent or preclude subsequent surgical dissection of
the lymph node bearing area. Above all, this procedure may
delay the proper treatment.
Unilateral or bilateral tonsillectomy should be per-
formed including excision of eventual remnant tonsillar
tissue. In the absence of panendoscopic detectable le-
sions, ipsilateral tonsillectomy can discover carcinoma in
about a quarter of the patients [164]. If physical examin-
ation shows mucosal abnormalities the detection rate
rises to 40%. It is still controversial if tonsillectomy
should be bilateral or unilateral. In favour of bilateral
tonsillectomy, some Authors report that the rate of
contralateral spread of metastatic cancer from occult
tonsil lesions may approach 10%. A more convincing
reason is to avoid asymmetric FDG uptake in the oro-
pharyngeal region by removing only one tonsil that may
confound follow up studies. For these reasons, bilateral
tonsillectomy is recommended as a routine step in the
search for the occult primary in patients presenting with
cervical metastasis of SCC and palatine tonsils intact
[165]. The discovery of the primary lesion may help the
radiation oncologist to better define volumes to be
treated and their respective dose. This ultimately would
help to increase the odds of cure and minimize the risk
of side effects. If physical examination and other imaging
modalities are negative, PET may discover new primaries
in an additional 25% of patients (5-73%), nodes in ≈ 15%
and distant metastases in ≈ 10% [166]. Because FDG-
PET detects increased metabolic activity, inflammation
induced by biopsies may contribute to false-positive
results if PET is obtained after direct laryngoscopy/
biopsy [167].
General treatment strategy
There are 2 main clinical scenarios:
1. MACROSCOPIC TUMOUR RESIDUAL AFTER
INITIAL EVALUATION: Surgery vs RT ± CT
Transversal section Coronal section
Figure 4 Parapharyngeal space (transversal and coronal sections).
Merlotti et al. Radiation Oncology  (2014) 9:264 Page 26 of 32In favour of neck surgery stand the following remarks:
1. If the patient most likely needs surgery after RT or
chemoRT (i.e. bulky node);
2. If the patient may be potentially cured by surgery
alone (i.e. small <3 cm/single node);
3. Surgery permits concomitant teeth extractions and
Direct Laringoscopy;
4. Surgery allows for a better staging of the neck and
pathology of node level involvement;
5. If more tissue is required and pathology of nodal
diffusion is uncertain.
However, surgery may add extra morbidity especially if
subsequent RT is necessary.
In favour of RT ± CT stand the following remarks:
1. If RT or CT-RT are potentially curative in patient
that would need postoperative RT anyhow
(i.e. multiple small nodes);
2. The use of RT or CT-RT without surgery on the
neck allows for a better oxygenation of the potential
mucosal site of primary;Table 22 Suggested fractionation regimens for Unknown
Primary (macroscopic disease present)
D (Gy) d (Gy) Fxs OTT (wks) Comment
CTV1 70 2 35 7
66 2.2 30 6 [168]
CTV2 63 1.8 35 7
CTV3 58.1 1.66 35 7
54 1.8 30 6 [168]3. It permits better evaluation of tumour response
(especially if CT is used); leaving salvage surgery for
non-responders.
2. NO RESIDUAL MACROSCOPIC DISEASE AFTER
INITIAL EVALUATION
If pN1 AND no ECE (AND no previous neck viola-
tion), observation can be appropriate; otherwise, if pN >
1 or ECE or neck violation, postoperative RT should be
recommended.
Target definition remarks
CTV1 or high disease volume that encompasses the
gross tumour volume in the neck if present with
a margin;
CTV2 that typically includes the putative primary site(s)
considered at high risk of containing microscopic disease;
moreover, after surgery, this would include the site of
dissected positive lymph nodes;
CTV3 includes the nodal stations that do not contain
positive or suspicious nodes after appropriate imaging;Table 23 Suggested fractionation regimens for Unknown
Primary (postoperative setting)
D (Gy) d (Gy) fxs OTT (wks) Comment
CTV2 60-64 2 30-32 6 (64 Gy if ECE+) [168]
63 1.8 30 6
CTV3 58.1 1.66 35 7
54 1.8 30 6
Merlotti et al. Radiation Oncology  (2014) 9:264 Page 27 of 32moreover, it would include the putative primary
site(s) considered at low risk of containing
microscopic disease.
Dose/fractionation remarks
Tables 22 and 23 show the commonly used fraction-
ation regimens in definitive (macroscopic nodal disease
present) and in postoperative settings:
Primary-tumour contour
1. According to classical teaching, the putative primary
tumour may be located in the pharyngeal axis and
thus the mucosa of the whole pharynx
(nasopharynx, oropharynx and hypopharynx) as well
as the larynx would be included in the subclinical
dose level; the oral cavity should NOT be routinely
included. The extent of the pharynx to be irradiated
must be determined on a case-by-case basis [169]:
a. Irradiation of oropharynx alone might be
sufficient for an HPV+ patient.
b. Irradiation of nasopharynx alone might be
sufficient for an EBV+.
2. The larynx and hypopharynx are considered at low
risk if levels III and IV are not involved and PET/CT
is negative and level V is positive and pathology is
suspicious for a nasopharyngeal primary or the
tumour stains for HPV and/or EBV. In these cases,
the dose to the larynx can be lowered to CTV3 or
even dropped from any CTV [168,170-173].
Lymphnode-level contour
1. Traditionally, all neck levels ipsilateral to the positive
nodal disease are included in the target volume.
2. With regard to the bilateral neck irradiation,
currently there are two points of view:
a. Considering the morbidity induced by extensive
irradiation, some Authors consider irradiation of
the contralateral neck indicated for a defined
subset of patients, e.g., those with bilateral nodal
metastases, extensive unilateral involvement with
regard to number and levels of nodal metastases
(cN2b+), unfavourable grading [164].
b. Other Authors, reporting local control rates with
median neck relapse rate ranging from 31 to 63%
after unilateral RT group, compared with a median
neck relapse rate ranging from 8 to 49% in bilateral
and pharyngeal mucosa RT group, advocate bilateral
neck irradiation [174]. In this case contralateral neck
levels II-IV and the retropharyngeal nodes could be
included in CTV3 [169].
3. Bilateral retropharyngeal nodes should be included.
4. Ipsilateral level Ib can be excluded if levels II and III
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